Skip to main content

Table 1 Efficacy and safety input data

From: Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain

Treatment Treatment success rate (%) Add-on rate (%) Severe AEs/switch due to severe AEs (%) Switch (due to other reason) (%) AE rate (%) Mortality rate (%)
Voriconazole 52.8 19.2 13.4 9.0 13.4 5.6
Liposomal amphotericin B 50.0 8.7 20.0 16.0 20.0 5.3
  1. Data sources:[14, 15].
  2. AE, adverse event.